Study drug IACS-6274 tested for advanced solid tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and agree to sign informed consent before any study steps.
- You have an advanced solid tumor confirmed by tumor biopsy or cell test.
- Your cancer has already had at least one prior treatment and is no longer responding (or standard options won’t help).
- Your last treatment was finished at least 3 weeks ago (or at least five “half-lives” of the drug), and side effects are mostly back to mild or stable.
- You can provide tumor tissue for mutation testing (a recent biopsy, or an older sample if it already has the needed mutation).
- Your body can handle treatment: adequate blood counts, kidney and liver function, and heart pumping function, plus you’re well enough to do normal activities (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This early-stage study tests ASKG915, a new treatment, for people with advanced solid cancers that are no longer responding to standard care (or don’t have standard options). If you may qualify, you’d be screened with recent health tests to check safety and eligibility, and then receive the study drug.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
Hear when a new Advanced Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.